![Matthew Ros](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Ros
Direktor/Vorstandsmitglied bei
COGENT BIOSCIENCES, INC.
Vermögen: 216 500 $ am 31.05.2026
Profil
Matthew E.
Ros is currently an Independent Director at Cogent Biosciences, Inc. since 2019.
Former roles include Chief Executive Officer & Director at Fore Biotherapeutics, Inc. from 2022 to 2023; Senior Director at Bristol Myers Squibb Co. from 1990 to 2007; Senior Vice President-Commercial Operations at ARIAD Pharmaceuticals, Inc. from 2009 to 2010; Vice President & Head-Franchise at Genzyme Corp.
from 2012 to 2014; Associate Vice President at Sanofi from 2010 to 2012; COO, VP & Global Head-Oncology Business Unit at Sanofi from 2014 to 2016; Chief Financial Officer at Epizyme, Inc. in 2021; Trustee at Cancer Care, Inc.; and Chief Operating Officer at Verastem, Inc. in 2025.
Education includes an undergraduate degree from The State University of New York, conferred in 1988.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VERASTEM, INC. 0.08% | 01.04.2025 | 50’000 ( 0.08% ) | 216 500 $ | 31.05.2026 |
| 13.04.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Matthew Ros
| Unternehmen | Position | Beginn |
|---|---|---|
| COGENT BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 26.07.2019 |
Ehemalige bekannte Positionen von Matthew Ros
| Unternehmen | Position | Ende |
|---|---|---|
| VERASTEM, INC. | Geschäftsführer | 15.12.2025 |
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Vorstandsvorsitzender | 01.08.2023 |
| EPIZYME, INC. | Finanzdirektor/CFO | 01.10.2021 |
| SANOFI | Geschäftsführer | 01.05.2016 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01.12.2014 |
Ausbildung von Matthew Ros
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
96
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Cogent Biosciences, Inc.
 Cogent Biosciences, Inc. BiotechnologyHealth Technology Discovers and develops new cellular immunotherapies for cancer | Health Technology |
Cancer Care, Inc.
 Cancer Care, Inc. Hospital/Nursing ManagementHealth Services Provides cancer treatment services | Health Services |
The State University of New York
 The State University of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
Verastem, Inc.
 Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Health Technology |
